Jenkins Abigail L. 4
4 · Aquestive Therapeutics, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Aquestive (AQST) Director Abigail Jenkins Receives Award
What Happened
Abigail L. Jenkins, a director of Aquestive Therapeutics, was granted a derivative award covering 50,500 underlying shares on June 10, 2026. The Form 4 reports the acquisition at $0.00 (i.e., a compensatory award/option grant rather than a cash purchase). The award vests 100% on June 10, 2027, subject to her continued service.
Key Details
- Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely filing).
- Reported terms: 50,500 underlying shares; reported acquisition price $0.00.
- Vesting: 100% of the underlying shares vest June 10, 2027, subject to continuous service (footnote F1).
- Shares owned after the transaction: not specified in the provided excerpt of the filing.
- Transaction type: Award/derivative grant (code A); not an immediate sale or open-market purchase.
Context
This was a compensatory derivative grant (options/award) to a director that vests one year after the grant date. No shares were exercised or sold at the time of the filing; value will depend on future vesting and any exercise terms. Such director awards are common as remuneration and do not on their own signal an insider purchase or sale of company stock.
Insider Transaction Report
- Award
Non-Qualified Stock Option (right to buy)
[F1]2026-06-10−50,500→ 50,500 totalExercise: $3.99From: 2027-06-10Exp: 2036-06-10→ Common Stock (50,500 underlying)
Footnotes (1)
- [F1]The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date.